David M. Santangelo - McDermott Will & Emery


David M. Santangelo represents life sciences and biopharmaceutical companies in a variety of corporate transactions and commercial undertakings with peer companies, universities and academic institutions, including licenses and collaborations, product acquisitions and dispositions, distribution arrangements, development agreements, manufacturing and supply agreements, services agreements, clinical trial agreements, sponsored research agreements, quality agreements and technology transfers. He advises industry clients at all stages of the product life cycle on their strategic alliances and all manner of commercial contracting relevant to both their daily operations and long-term planning. David serves as an outside general counsel to many early stage and smaller clients, and as a trusted advisor to more mature, middle market and large cap companies, both public and private.

Show More


  • Represented Icosavax, EQRx International, Scaffold Therapeutics, AffyImmune Therapeutics, Charles River Laboratories, Pasithea Therapeutics, Spine BioPharma, Deerfield Management, Societal CDMO (f/k/a Recro Gainesville)*, Baudax Bio*, Seagen (f/k/a Seattle Genetics)*, Enterin*, Aro Biotherapeutics*, Windtree Therapeutics*, Edwards Lifesciences*, Code Bio*, KBP Biosciences*, Personal Genome Diagnostics (PGDx)*, FlowMetric*, Cognition Therapeutics*, TELA Bio*, BioXcel Therapeutics*, Purdue Pharma* and/or their affiliates or portfolio companies in connection with the negotiation of various research, development, collaboration, material transfer, manufacturing, supply, distribution, services, clinical trial, quality assurance and similar arrangements.
  • Represented Organicell Regenerative Medicine in its negotiation and entry into a Joint Development Agreement and Supply Agreement with The Beauty Health Company (NASDAQ: SKIN) to create a first-to-market exosome booster that will address signs of aging and inflammation in the skin by leveraging novel exosome technology based regenerative medical therapies that, once developed, will be available as a customized treatment addition for Beauty Health Company’s flagship brand, Hydrafacial.
  • Represented Surgical Planning Associates, Inc. (SPA) in its negotiation and entry into an exclusive co-marketing agreement with Zimmer, Inc., an affiliate of Zimmer Biomet Holdings Inc. (NYSE: ZBH), pursuant to which SPA granted to Zimmer, Inc. the exclusive right to market SPA’s mixed reality guidance system approved by the FDA, better known as HipInsight, for use in navigation and mixed augmented reality guidance for hip arthroplasty, in combination with SPA’s pre-operative CT-based 3D planning process for hip arthroplasty.

Show More


Northwestern University Pritzker School of Law, JD, 2001
Cornell University, BA, with distinction, 1998

New York